**Influence of isoflurane on the diastolic pressure-flow relationship and critical occlusion pressure during Arterial CABG Surgery: A randomized controlled trial**

José Hinz, Ashham Mansur, Gerd G Hanekop, Andreas Weyland, Aron F Popov, Jan D Schmitto, Frank FG Grüne, Martin Bauer, Stephan Kazmaier

The effects of isoflurane on the determinants of blood flow during coronary artery bypass graft (CABG) surgery are not completely understood. This study characterized the influence of isoflurane on the diastolic pressure-flow (P-F) relationship and critical occlusion pressure (COP) during CABG surgery. Twenty patients undergoing CABG surgery were studied. Patients were assigned to an isoflurane or control group. Hemodynamic and flow measurements during CABG surgery were performed twice (15 minutes after the discontinuation of extracorporeal circulation (T15) and again 15 minutes later (T30)). The zero flow pressure intercept (a measure of COP) was extrapolated from a linear regression analysis of the instantaneous diastolic P-F relationship. In the isoflurane group, the application of isoflurane significantly increased the slope of the diastolic P-F relationship by 215% indicating a mean reduction of coronary vascular resistance (CVR) by 46%. Simultaneously, the mean diastolic aortic pressure (MDAP) decreased by 19% mainly due to a decrease in the systemic vascular resistance index by 21%. The COP, cardiac index, heart rate, left ventricular end-diastolic pressure (LVEDP) and coronary sinus pressure (CSP) did not change significantly. In the control group, the parameters remained unchanged. In both groups, COP significantly exceeded the CSP and LVEDP at both time points. We conclude that short-term application of isoflurane at a sedative concentration markedly increases the slope of the instantaneous diastolic P-F relationship during CABG surgery implying a distinct decrease with CVR in patients undergoing CABG surgery.
Influence of Isoflurane on the Diastolic Pressure-Flow Relationship and Critical Occlusion Pressure during Arterial CABG Surgery: A randomized controlled trial

Jose Hinz¹, Ashham Mansur*¹, Gerd Gunnar Hanekop¹, Andreas Weyland², Aron Frederik Popov³, Jan Dieter Schmitto⁴, Frank Grüne⁵, Martin Bauer¹, Stephan Kazmaier¹

¹Department of Anesthesiology, University Medical Center Goettingen, Georg-August-University Goettingen, D-37075 Goettingen, Germany

²Department of Anesthesiology and Intensive Care Medicine, Medical Center Oldenburg, Germany

³Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield Hospital, London, United Kingdom

⁴Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany

⁵Department of Anesthesiology, Erasmus MC, Rotterdam, the Netherlands
Abstract

The effects of isoflurane on the determinants of blood flow during coronary artery bypass graft (CABG) surgery are not completely understood. This study characterized the influence of isoflurane on the diastolic pressure-flow (P-F) relationship and critical occlusion pressure (COP) during CABG surgery. Twenty patients undergoing CABG surgery were studied. Patients were assigned to an isoflurane or control group. Hemodynamic and flow measurements during CABG surgery were performed twice (15 minutes after the discontinuation of extracorporeal circulation (T15) and again 15 minutes later (T30)). The zero flow pressure intercept (a measure of COP) was extrapolated from a linear regression analysis of the instantaneous diastolic P-F relationship. In the isoflurane group, the application of isoflurane significantly increased the slope of the diastolic P-F relationship by 215% indicating a mean reduction of coronary vascular resistance (CVR) by 46%. Simultaneously, the mean diastolic aortic pressure (MDAP) decreased by 19% mainly due to a decrease in the systemic vascular resistance index by 21%. The COP, cardiac index, heart rate, left ventricular end-diastolic pressure (LVEDP) and coronary sinus pressure (CSP) did not change significantly. In the control group, the parameters remained unchanged. In both groups, COP significantly exceeded the CSP and LVEDP at both time points. We conclude that short-term application of isoflurane at a sedative concentration markedly increases the slope of the instantaneous diastolic P-F relationship during CABG surgery implying a distinct decrease with CVR in patients undergoing CABG surgery (Registration trial DRKS00008892 on DRKS).
Introduction

In a theoretical approach to the pressure-flow (P-F) relationship in arterioles, these calculations are a simplification of the actual variable tissue characteristics in the vascular bed of an organ (Hoffman & Spaan 1990). We demonstrated in an earlier study on the diastolic coronary P-F relationship that the effective downstream pressure is not determined by coronary sinus pressure (CSP) or left ventricular end-diastolic pressure (LVEDP) but by the critical occlusion pressure (COP) of the coronary vasculature, which was considerably higher than both parameters (Kazmaier et al. 2006). The zero flow pressure intercept as a measure of COP was extrapolated from the linear regression analysis of the instantaneous diastolic P-F relationship.

However, the effects of isoflurane on the determinants of blood flow during coronary artery bypass graft (CABG) surgery are not completely understood. Earlier investigations yielded discrepant findings on the risk of myocardial ischemia due to the vasoactive potency of isoflurane. Some investigations found that the risk of myocardial ischemic events due to coronary flow misdistribution is increased when anesthesia is maintained with isoflurane (Buffington et al. 1987; Diana et al. 1993; Inoue et al. 1990; Khambatta et al. 1988; Priebe & Foex 1987). In contrast, results from other investigators demonstrated that the risk of perioperative myocardial ischemia was not increased during isoflurane anesthesia compared with other volatile anesthetics or total intravenous anesthetic regimens (Leung et al. 1991; Pulley et al. 1991). Furthermore, in some studies, the vasoactive potency of isoflurane positively affected the regional distribution of coronary blood flow (Hartman et al. 1990; Kim et al. 1994). However, regarding volatile anesthetics, maximal increases in global coronary blood flow were obtained during isoflurane anesthesia (Crystal et al. 2000). According to the fact that volatile anesthetics (Landoni et al. 2013) and in particular isoflurane are beneficial for myocardial
ischemia and has been shown to improve survival in cardiac surgery (Bignami et al. 2013; Chiari et al. 2005; Ge et al. 2010; Lang et al. 2013), this study aimed at investigating the impact of isoflurane on the diastolic P-F relationship and COP during CABG surgery.
Patients and Methods

Patients

This study was approved by the University of Goettingen ethics committee in Goettingen, Germany (12/4/04) and conformed to the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all patients. Twenty patients (17 males and 3 females) with angiographically verified coronary artery disease (CAD) were studied following elective CABG surgery. Biometric and intraoperative data are presented in table 1. Patients with concomitant valvular heart disease or a lack of sinus rhythm at the start of the measurement period were excluded from this study. Antiarrhythmic and antihypertensive medications (except angiotensin-converting enzyme (ACE) inhibitors) were continued until the day of surgery. The pre-anesthetic medication consisted of 1.0 mg of flunitrazepam per os on the evening prior to surgery and 60 minutes before the induction of general anesthesia. Patients were pre-operatively randomly assigned to receive either total intravenous anesthesia during the complete study period (control group) or an additional 0.4% volume of isoflurane (1.0 minimum anesthetic concentration (MAC)_{sedative}, isoflurane group) immediately after the baseline measurements.

Methods

Before the induction of anesthesia, electrocardiogram leads were placed, and a 15-gauge catheter (PV2015L20; Pulsion GmbH, Munich, Germany) was placed in the femoral artery to measure the mean arterial pressure (MAP). Cardiac output measurements were performed with a transpulmonary thermodilution technique, pulse contour analysis (PiCCO, Pulsion GmbH, Munich, Germany) and blood sampling. Intravenous induction of anesthesia was performed with 2.0 μg kg^{-1} sufentanil and 0.1 mg kg^{-1} pancuronium bromide to facilitate endotracheal intubation.
Subsequently, a central venous catheter (8.5 Fr., 4-lumen; ARROW GmbH, Erding, Germany) was inserted via the right internal jugular vein to measure central venous pressure (CVP) and for drug and fluid administration.

Maintenance of total intravenous anesthesia was performed by continuous infusion of sufentanil (3.0 \( \mu \text{g kg}^{-1} \text{h}^{-1} \)) and additive boluses of midazolam if necessary. The patients’ lungs were ventilated by intermittent positive pressure ventilation (Cicero; Draeger GmbH, Lübeck, Germany). The respiratory rate and minute volume were adjusted to achieve normocapnia. During the measurement period, the fraction of inspired oxygen \((\text{F}_{\text{i}}\text{O}_2)\) was 0.5 to avoid hypoxemic events.

Extracorporeal circulation with standard techniques included two-stage venous cannulation (Medtronic MC2TM, 91246C; 34/46Fr.; Medtronic Inc., Minneapolis, USA), central aortic cannulation (Aortic Arch Cannula-Straight/Wire Inlay, 6.5 mm, A232-65; Stöckert Instrumente GmbH, Munich, Germany) and membrane oxygenation (Hilate\textsuperscript{®} 7000; Medizintechnik AG, Stolberg, Germany). Surgery was performed during aortic cross-clamping and cardioplegic arrest with combined anterograde and retrograde cold blood cardioplegia (Dr. Franz Köhler Chemie GmbH, Alsbach-Hähnlein, Germany).

**Measurements**

The coronary vascular resistance (CVR) was calculated as the ratio of coronary perfusion pressure (CPP) and coronary blood flow. CPP was calculated as the difference between the upstream pressure and downstream pressure. The coronary upstream pressure was expressed as the mean diastolic aortic pressure. CSP and LVEDP are generally used as equivalents of coronary downstream pressure (reflecting the specific characteristics of the coronary anatomy).
Baseline measurements were performed 15 minutes ($T_{15}$) after the discontinuation of extracorporeal circulation under steady state conditions. Fifteen minutes after the end of the first measurement period ($T_{30}$), a second measurement period was performed in which patients in the isoflurane group received 0.4% volume of isoflurane for 15 minutes. In the control group, the anesthetic regimen did not change between the two measurement periods. All of the measurements were performed prior to the reversal of heparin. At the beginning of each measurement period, cardiac output was assessed by the transpulmonary thermodilution method as the mean of three injections of 15 ml of ice-cooled isotonic saline solution randomly distributed over the respiratory cycle. During the short period (5 to 10 seconds) of coronary blood flow measurements, the patient was disconnected from the ventilator to avoid intrapleural pressure changes and volume shifts that might influence the P-F relationships. In this study, to avoid capacitance effects of the arterial vessel by opening phenomena, the analysis of the P-F relationship only included data from the highest diastolic flow rate in the arterial bypass graft until the end of diastole.

Flow measurements were performed using ultrasound and calculations based on the transit time principle (Cardiomedi 4008; Quick-Fit probes (size 2.0-3.0 mm), Medistim, Norway). The flow in the left internal mammary artery and pressure measurements were recorded simultaneously over a period of 5 seconds using analogue-digital converting devices with a sampling frequency of 500 Hz.

The measurements of aortic pressure and CSP were recorded via the cannulae for the extracorporeal circuit and retrograde blood cardioplegia, respectively (coronary sinus cannula: retrograde cardioplegia cannula RSH-M014S, 14 Fr; Chase Medical, Richardson, Texas, USA). LVEDP values were obtained using a left atrial catheter (Jostra KLAP1751 pressure monitoring...
catheter, 5.0 Fr; Jostra AG, Hirrlingen, Germany) introduced via the upper right pulmonary vein and positioned trans-mitally into the left ventricle during the study period.

Arterial and coronary sinus blood samples were obtained immediately after each period of coronary blood flow measurement for the determination of pH (pH_{art}, pH_{cs}), acid base status, arterial and coronary sinus blood gas tensions (P_{aO_2}, P_{csO_2}, P_{aCO_2}, P_{csCO_2}), oxygen saturation (S_{aO_2}, S_{csO_2}), hemoglobin (Hb) and lactate concentrations (ABL 700; Radiometer Medical A/S, Denmark). In the isoflurane group, additional coronary sinus blood samples were obtained after the second measurement period for the determination of isoflurane plasma concentrations.

Calculations

The cardiac index (CI), stroke volume index (SVI) and systemic vascular resistance index (SVRI) were calculated according to standard formulae. The critical occlusion pressure was calculated by extrapolation of the linear regression analysis of the diastolic part of the aortic P-F loop to the zero flow pressure intercept (2). The mean LVEDP was assessed by analysis of the left ventricular pressure curve for every beat during the study period. The CSP was calculated as the mean CSP of the entire period of flow measurements.

Statistics

Statistical procedures were performed using the Statistical Package for the Social Sciences (SPSS) (SPSS 17.0 for MAC; SPSS Inc., Chicago, Illinois, USA). Results are expressed as medians and ranges. Two continuous variables were compared using Mann-Whitney test. Linear regression analysis was performed using flow as the dependent variable and diastolic aortic pressure as the independent variable. A p-value less than 0.05 was considered to be significant.
Results

The biometric and perioperative data of the studied patients were not different between both groups (table 1). The data from five consecutive heart beats were analyzed for each patient; none of the patients had to be excluded due to missing data or artifacts in hemodynamics and flow measurements.

Table 1. Biometric and intraoperative data. Results are presented as medians and ranges, if required.

|                          | Control (n = 10) | Isoflurane (n = 10) | p-value |
|--------------------------|-----------------|--------------------|---------|
| Age (years)              | 70 (58–79)      | 71 (51–81)         | 0.44    |
| Weight (kg)              | 80 (60–92)      | 75 (60–103)        | 0.68    |
| Height (cm)              | 168 (153–82)    | 168 (156–180)      | 0.68    |
| Gender (male/female)     | 8/2             | 9/1                | 0.53    |
| Body surface area (m²)   | 1.89 (1.57–2.12)| 1.89 (1.59–2.09)   | 0.97    |
| Coronary artery disease  |                 |                    |         |
| 3 vessel disease, n = 7  |                 | 3 vessel disease, n = 6 |
| 2 vessel disease, n = 3  |                 | 2 vessel disease, n = 3 |
| 1 vessel disease, n = 1  |                 | 1 vessel disease, n = 1 |
| Grafts (n)               | 4 (3–5)         | 4 (2–5)            |         |
| Aortic clamping time (minutes) | 78 (61–92) | 85 (45–112)       | 0.68    |
| Reperfusion time (minutes) | 44 (32–65)  | 40 (26–66)        | 0.48    |

Systemic hemodynamics
In both groups, GEDI and SVV (parameters of volume status), as well as LVEDP, CFI, and EVLWI, did not change during the entire measurement period and were not different between groups. In the control group, MAP, CI, HR and SVRI did not change during the entire study period. In contrast to measurements in the control group, the application of 1.0 MAC\textsubscript{sedative} isoflurane decreased MAP from 69 to 57 mmHg (17%) and SVRI from 1730 to 1364 dyn sec cm\textsuperscript{-5} m\textsuperscript{2} (21%) but had no effect on HR and CI. The systemic hemodynamic data are summarized in table 2 (Table 2a and Table 2b).

Table 2. Hemodynamic data. Results are presented as medians and ranges.

|                  | Control | Isoflurane |
|------------------|---------|------------|
|                  | T\textsubscript{15} | T\textsubscript{30} | T\textsubscript{15} | T\textsubscript{30} | T\textsubscript{15} | T\textsubscript{30} |
| CI (l min\textsuperscript{-1} m\textsuperscript{2}) | 2.9 (2.3–3.6) | 2.7 (2.1–3.2) | 0.11 | 2.7 (1.6–5.7) | 2.6 (1.9–5.8) | 0.28 |
| HR (min\textsuperscript{-1}) | 89 (53–106) | 90 (56–106) | 0.65 | 99 (76–112) | 88 (74–100) | 0.15 |
| MAP (mmHg) | 65 (47–80) | 66 (56–84) | 0.06 | 69 (59–85) | 57 (48–59) | 0.005 |
| MDAP (mmHg) | 57 (45–64) | 60 (43–71) | 0.06 | 62 (53–79) | 50 (45–57) | 0.005 |
| DDT (ms) | 447 (257–1215) | 489 (366–1070) | 0.60 | 721 (240–919) | 567 (339–937) | 0.33 |
| CVP (mmHg) | 9 (7–16) | 9 (7–16) | 1.0 | 10 (7–12) | 10 (7–13) | 0.82 |
| Parameter          | Mean (Range) | SD | Mean (Range) | SD |
|-------------------|--------------|----|--------------|----|
| CSP (mmHg)        | 14 (8–18)    | 13 (7–18) | 0.39 | 10 (5–20) | 10 (6–19) | 0.44 |
| SVRI (dyn sec cm$^{-5}$ m$^{-2}$) | 1555 (809–2454) | 1716 (1355–2193) | 0.31 | 1730 (850–2969) | 1364 (699–1965) | 0.04 |
| GEDI (ml m$^{-2}$) | 642 (541–895) | 652 (594–883) | 0.78 | 642 (457–834) | 617 (479–802) | 0.92 |
| EVLWI (ml m$^{-2}$) | 6.8 (5.7–10.0) | 6.3 (5.0–8.7) | 0.62 | 7.4 (4.0–10.7) | 7.0 (4.3–10.0) | 0.16 |
| LVEDP (mmHg)      | 16 (8–33)    | 15 (8–30) | 0.09 | 11 (8–37) | 13 (9–22) | 0.80 |
| SVV (%)           | 11 (6–17)    | 12 (5–18) | 0.64 | 12 (5–19) | 14 (8–16) | 0.43 |
| dp/dt$_{max}$ (mmHg s$^{-1}$) | 766 (507–1063) | 763 (500–887) | 0.65 | 748 (510–1350) | 651 (340–1143) | 0.02 |
| CFI (min$^{-1}$)  | 4.2 (3.5–5.0) | 3.7 (2.8–5.0) | 0.05 | 4.6 (2.5–8.1) | 3.9 (3.1–7.4) | 0.16 |
| COP (mmHg)        | 39 (23–48)   | 42 (28–44) | 0.25 | 35 (26–59) | 34 (27–42) | 0.11 |
| FLOW (ml/min)     | 26 (10–38)   | 22 (9–53) | 0.72 | 29 (7–68) | 23 (11–50) | 0.24 |
| Slope (B1)        | 1.36 (0.48–2.71) | 1.29 (0.46–2.10) | 0.49 | 0.94 (0.50–4.82) | 2.03 (0.56–4.41) | 0.02 |
| CVR               | 0.74         | 0.78 (0.48–1.06) | 0.49 | 1.06 | 0.51 (0.23–0.007) | 0.007 |
### Table 3. Hemodynamic data; Isoflurane vs control.

|                      | Control vs Isoflurane T15 (p-value) | Control vs Isoflurane T30 (p-value) |
|----------------------|-------------------------------------|-------------------------------------|
| CI (l min⁻¹ m⁻²)     | 0.96                                | 0.90                                |
| HR (min⁻¹)           | 0.90                                | 0.85                                |
| MAP (mmHg)           | 0.06                                | 0.009                               |
| MDAP (mmHg)          | 0.06                                | 0.01                                |
| DDT (ms)             | 0.56                                | 0.90                                |
| CVP (mmHg)           | 0.96                                | 0.83                                |
| CSP (mmHg)           | 0.16                                | 0.11                                |
| SVRI (dyn sec cm⁻⁵ m⁻²)| 0.51                              | 0.05                                |
| Parameter          | Mean | SD  |
|-------------------|------|-----|
| GEDI (ml m⁻²)     | 0.69 | 0.27|
| EVLWI (ml m⁻²)    | 0.31 | 0.41|
| LVEDP (mmHg)      | 0.34 | 0.47|
| SVV (%)           | 0.96 | 0.57|
| dp/dtmax (mmHg s⁻¹)| 0.96 | 0.57|
| CFI (min⁻¹)       | 0.56 | 0.76|
| COP (mmHg)        | 0.87 | 0.11|
| FLOW (ml/min)     | 0.38 | 0.79|
| Slope (B1)        | 0.79 | 0.05|
| CVR from Slope 1/B1| 0.87 | 0.14|
| CVR from CSP      | 0.83 | 0.28|
| CVR from LVEDP    | 0.85 | 0.39|
| CVR from COP      | 0.73 | 0.10|

The diastolic flow and COP during CABG surgery did not differ between measurement periods or groups. In the control group, COP exceeded LVEDP by 244% and 280%, respectively. In the control group, COP exceeded CSP by 279% and 323%, respectively. In the isoflurane group, similar results were found with 318%, 262%, 350% and 340%, respectively.

The application of isoflurane decreased the MDAP from 62 mmHg to 50 mmHg, whereas MDAP did not change in the control group.

Consequently, CVR changes were only observed in the isoflurane group (if calculated using COP and LVEDP but not CSP). Considerable differences in CVR were observed depending on the downstream pressure (COP, LVEDP or CSP) used in the formula. With CSP as a measure of...
downstream pressure, CVR did not change significantly in either group. In the control group, the CVR values were 1.73 and 1.83 mmHg ml\(^{-1}\) minute, while those in the isoflurane group were 1.8 and 1.35 mmHg ml\(^{-1}\) minute. Similar findings were observed for CVR calculated with LVEDP in both groups.

In contrast to these findings, using COP in the formula indicated that CVR was decreased after the application of isoflurane from 1.06 to 0.51 mmHg ml\(^{-1}\) minute. In the control group, CVR was calculated using COP, and no differences were observed (0.74 and 0.78 mmHg ml\(^{-1}\) minute). As expected, using COP for the calculation of CVR resulted in significantly lower values for CVR than using LVEDP or CSP. The CVR values were identical when calculated according to the slope of the instantaneous diastolic P-F relationship. The diastolic flow, COP and CVR calculations are summarized in table 2 (Table 2a and Table 2b).

Arterial blood gas analyses and acid base status also did not differ between groups and remained unchanged during the measurement period. For the coronary sinus blood gas samples, \(S_{cs}O_2\), \(p_{cs}O_2\), \(p_{cs}CO_2\), \(pH_{cs}\), \(BE_{cs}\) and \(SBIC_{cs}\) and lactate did not differ between the measurement periods in the control group. In contrast to these findings, the application of isoflurane led to a significant increase in \(S_{cs}O_2\) and \(p_{cs}O_2\) by 22% and 22%, respectively, indicating a reduced myocardial oxygen extraction. This decrease in myocardial oxygen extraction was not associated with a significant change in MLE. The arterial and coronary sinus blood gas analysis results are presented in table 3 (Table 3a and Table3b).

### Table 4. Arterial and coronary sinus blood gas analyses. Results are presented as medians and ranges.

|                  | Control          |                  | Isoflurane       |                  |
|------------------|------------------|------------------|------------------|------------------|
|                  | \(T_{15}\)       | \(T_{30}\)       | \(T_{15}\)       | \(T_{30}\)       | \(T_{15}\)       | \(T_{30}\)       | Isoflurane        |
|                  |                  |                  | \(T_{15}\)       | \(T_{30}\)       |                  |                  |                  |
| \(Hb_{art}\) (g/dl) | 9.1 (7.5–10.0)   | 9.0 (7.8–10.9)   | 0.51             | 9.2 (8.1–10.3)   | 9.2 (7.6–11.6)   | 0.91             |
### Table 5. Arterial and coronary sinus blood gas analyses; Isoflurane vs Control.

|                      | Control vs Isoflurane | Control vs Isoflurane |
|----------------------|-----------------------|-----------------------|
|                      | T15 (p-value)         | T30 (p-value)         |
| Hb<sub>art</sub> (g/dl) | 0.43                  | 0.57                  |
| S<sub>a</sub>O<sub>2</sub> (%) | 0.17                  | 0.32                  |
| P<sub>a</sub>O<sub>2</sub> (mmHg) | 0.32                  | 0.08                  |
| P<sub>a</sub>CO<sub>2</sub> (mmHg) | 0.39                  | 0.12                  |
| pH<sub>art</sub>      | 0.35                  | 0.68                  |
| BE<sub>art</sub> (mmol/l) | 0.22                  | 0.25                  |
| Parameter                  | Value 1 | Value 2 |
|---------------------------|---------|---------|
| SBIC_{art} (mmol/l)       | 0.19    | 0.25    |
| S_{cs}O_{2} (%)           | 0.85    | 0.17    |
| P_{cs}O_{2} (mmHg)        | 0.58    | 0.17    |
| P_{cs}CO_{2} (mmHg)       | 0.80    | 0.35    |
| pH_{cs}                   | 0.79    | 0.85    |
| BE_{cs} (mmol/l)          | 0.53    | 0.17    |
| SBIC_{cs} (mmol/l)        | 0.63    | 0.16    |
| Lactate_{cs} (mmol/l)     | 0.06    | 0.03    |
| Isoflurane_{cs} (µg/dl)   |         |         |
This study investigated the influence of short-term isoflurane administration on the instantaneous diastolic P-F relationship for the calculation of CVR and COP in patients undergoing elective CABG surgery. CVR was calculated with different techniques. First, CVR was calculated with conventional formulas using MDAP as the upstream pressure and LVEDP or CSP as the downstream pressures. Second, CVR was calculated from the instantaneous diastolic P-F relationship using either the slope of the linear diastolic portion or the linear extrapolation of this slope to zero flow (with COP for the calculation of downstream pressure). COP was about two to three times higher than the generally used downstream pressures (CSP or LVEDP) and was not influenced by isoflurane. This result may be explained by a waterfall phenomenon in the coronary circulation (Kazmaier et al. 2006; Maas et al. 2012). In addition, CVR decreased following the application of isoflurane only when the instantaneous P-F relationship was used in the calculation. The CVR decreases derived from the P-F relationship showed excellent concordance. The finding of reduced CVR was supported by decreased myocardial oxygen extraction in the isoflurane group.

COP is calculated by linear extrapolation of the instantaneous diastolic P-F relationship in the respective grafts to zero flow. Similarly, but without extrapolation to zero flow, CVR can be assessed by the slope of the instantaneous diastolic P-F relationship. The determination COP in IMAB grafts for calculating CPP and CVR revealed that both CSP and LVEDP (generally used as measures of downstream pressure to calculate CPP and CVR) underestimate the effective downstream pressure and, consequently, CVR.
The concept of using COP to define the effective downstream pressure is convincing because basic physiology predicts that blood flow ceases if the difference between the upstream and downstream pressure in a vascular tree equals zero; thus, the arterial pressure at zero flow represents the effective downstream pressure of organ blood flow (Hoffman & Spaan 1990).

Earlier experimental and clinical studies investigating the effects of massive coronary vasodilatation on diastolic P-F demonstrated that the linearity of the relationship between pressure and flow velocity was not influenced. The slope increased and COP decreased after vasodilatation in these studies (Dole et al. 1984; Klocke et al. 1981; Nanto et al. 2001). Intracoronary injections of angiographic contrast medium or adenosine triphosphate depressed vasomotor activity and induced an atrioventricular blockade followed by a non-physiological increase in diastole.

In contrast to these studies, we found a remarkable decrease in CVR only when COP was used to calculate the effective perfusion pressure and CVR. As expected, the calculation of CVR using the instantaneous diastolic P-F relationship yielded identical results. Using CSP and LVEDP as downstream pressures to calculate CPP and CVR revealed unchanged CPP and CVR. CSP and LVEDP may not adequately reflect downstream pressure (Kazmaier et al. 2006). In earlier studies, blood flow velocity measurements were performed (in contrast to our study in which blood flow was assessed). The relative accuracy of flow probes has been described and validated (within ±2%) (Beldi et al. 2000; Groom et al. 2001). Flow velocity is linearly related to flow only if the diameter of the vessel in which the measurements are performed is calculated. Studies have demonstrated that the cross-sectional areas of epicardial coronary vessels are nearly independent of pressure and flow (Douglas & Greenfield 1970; Klocke et al. 1980). Thus, differences in
results are probably not due to different measurement techniques but to different study conditions.

Furthermore, it remains questionable whether the CVR and COP results assessed in the previously mentioned studies during maximal coronary vasodilatation and atrioventricular blockade reflect physiologic conditions in human coronary circulation as presented in our study. Most studies on intraoperative myocardial blood flow measurements are focused on graft patency (D'Ancona et al. 2000; Leung et al. 1991; Takami & Ina 2001; Walpoth et al. 1998). In our first study, we demonstrated the feasibility of calculating COP, CPP and CVR by assessing the instantaneous P-F relationship in coronary bypass grafts (Kazmaier et al. 2006). In another study, a negative correlation was observed between COP and residual myocardial viability after angioplasty in patients with acute myocardial infarction (Shimada et al. 2003). In a group of similar patients, short- and long-term myocardial outcomes were closely correlated with the deceleration time of diastolic coronary flow velocity (Furber et al. 2004; Yamamuro et al. 2002).

Several studies have demonstrated the myocardial protective effects of isoflurane in patients undergoing CABG surgery. Nevertheless, in our study, isoflurane did not influence COP (in contrast to CPP and CVR). Additionally, CPP was considerably overestimated if CSP or LVEDP, which were not influenced by isoflurane, were used in the calculations.

In addition to providing a more valid calculation of CPP using COP for downstream pressure, our study also has clinical implications. After short-term application of isoflurane with sub-anesthetic concentrations, COP was unchanged, but MDAP decreased significantly, resulting in a remarkable decrease in CPP. Despite this decrease in CPP, coronary flow remained unchanged, which is due to a considerable decrease in CVR. These effects could only be measured by the calculation of CVR using the diastolic instantaneous P-F relationship (in contrast to the standard
formula). Undiminished flow was accompanied by an unaltered CI. Nevertheless, we observed increased ScsO$_2$, which is an indicator of hyper-perfusion.

Our study had a few limitations that may affect the interpretation of these results. The second measurement in the isoflurane group was performed after 15 minutes of isoflurane application. The expiratory isoflurane concentrations reached 95% of the inspiratory concentrations indicating steady state conditions in the isoflurane blood concentrations at 1.0 MAC$_{\text{sedative}}$. Nevertheless, we cannot exclude the possibility that the myocardial uptake of isoflurane was incomplete resulting in unstable concentrations in the myocardial tissue. Studies on long-term applications and dose-response relationships of isoflurane may provide further insights on the effects of isoflurane on the instantaneous P-F relationship in arterial coronary bypass grafts.
Conclusions

Short-term application of isoflurane with sub-sedative concentrations markedly increased the slope of the instantaneous diastolic P-F relationship in arterial coronary bypass grafts. This finding implies a distinct decrease in CVR in patients undergoing CABG surgery that cannot be observed with the conventional CVR calculations using MDAP as the upstream pressure and LVEDP or CSP as the downstream pressure. The simultaneous decrease in myocardial oxygen extraction supports the validity of CVR calculation using the slope of the diastolic P-F relationship possibly indicating hyper-perfusion of the myocardium. Thus, the technique provides a more rational approach for the measurement of regional coronary vascular perfusion.

Independent of the anesthetic, CSP and LVEDP greatly underestimated the effective downstream pressure and COP leading to a systematic overestimation of CPP. This result can be explained by a vascular waterfall phenomenon in the coronary circulation. However, in contrast to CVR, COP (the more reliable downstream pressure) is not influenced by isoflurane.
Acknowledgments

The authors thank the staff of the Department of Anesthesiology all of whom were involved in patient care and monitoring.
References

Beldi G, Bosshard A, Hess OM, Althaus U, and Walpoth BH. 2000. Transit time flow measurement: experimental validation and comparison of three different systems. *Ann Thorac Surg* 70:212-217.

Bignami E, Greco T, Barile L, Silvetti S, Nicolotti D, Fochi O, Cama E, Costagliola R, Landoni G, Biondi-Zoccai G, and Zangrillo A. 2013. The effect of isoflurane on survival and myocardial infarction: a meta-analysis of randomized controlled studies. *J Cardiothorac Vasc Anesth* 27:50-58. 10.1053/j.jvca.2012.06.007

Buffington CW, Romson JL, Levine A, Duttlinger NC, and Huang AH. 1987. Isoflurane induces coronary steal in a canine model of chronic coronary occlusion. *Anesthesiology* 66:280-292.

Chiari PC, Bienengraeber MW, Pagel PS, Krolkowski JG, Kersten JR, and Warrtler D. 2005. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. *Anesthesiology* 102:102-109.

Crystal GJ, Zhou X, Gurevicius J, Czinn EA, Salem MR, Alam S, Piotrowski A, and Hu G. 2000. Direct coronary vasomotor effects of sevoflurane and desflurane in in situ canine hearts. *Anesthesiology* 92:1103-1113.

D'Ancona G, Karamanoukian HL, Ricci M, Bergsland J, and Salerno TA. 2000. Graft patency verification in coronary artery bypass grafting: principles and clinical applications of transit time flow measurement. *Angiology* 51:725-731.

Diana P, Tullock WC, Gorcsan J, 3rd, Ferson PF, and Arvan S. 1993. Myocardial ischemia: a comparison between isoflurane and enflurane in coronary artery bypass patients. *Anesth Analg* 77:221-226.

Dole WP, Richards KL, Hartley CJ, Alexander GM, Campbell AB, and Bishop VS. 1984. Diastolic coronary artery pressure-flow velocity relationships in conscious man. *Cardiovasc Res* 18:548-554.

Douglas JE, and Greenfield JC, Jr. 1970. Epicardial coronary artery compliance in the dog. *Circ Res* 27:921-929.

Furber AP, Prunier F, Nguyen HC, Boulet S, Delepine S, and Geslin P. 2004. Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events. *Circulation* 110:3527-3533. 10.1161/01.cir.0000148686.95696.1e

Ge ZD, Pravdic D, Bienengraeber M, Pratt PF, Jr., Auchampach JA, Gross GJ, Kersten JR, and Warrtler D. 2010. Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. *Anesthesiology* 112:73-85. 10.1097/ALN.0b013e3181c4a607

Groom R, Tryzelaar J, Forest R, Niimi K, Cecere G, Donegan D, Katz S, Weldner P, Quinn R, Braxton J, Blank S, Kramer R, and Morton J. 2001. Intra-operative quality assessment of coronary artery bypass grafts. *Perfusion* 16:511-518.

Hartman JC, Kampilne JP, Schmeling WT, and Warrtler DC. 1990. Volatile anesthetics and regional myocardial perfusion in chronically instrumented dogs: halothane versus isoflurane in a single-vessel disease model with enhanced collateral development. *J Cardiotorac Anesth* 4:588-603.

Hoffman JJ, and Span A. 1990. Pressure-flow relations in coronary circulation. *Physiol Rev* 70:331-390.

Inoue K, Reichelt W, el-Banayosy A, Minami K, Dallmann G, Hartmann N, and Windeler J. 1990. Does isoflurane lead to a higher incidence of myocardial infarction and perioperative death than enflurane in coronary artery surgery? A clinical study of 1178 patients. *Anesth Analg* 71:469-474.
Kazmaier S, Hanekop GG, Grossmann M, Dorge H, Gotze K, Schondube F, Quintel M, and Weyland A. 2006. Instantaneous diastolic pressure-flow relationship in arterial coronary bypass grafts. *Eur J Anaesthesiol* 23:373-379. 10.1017/s0265021505001985

Khambatta HJ, Sonntag H, Larsen R, Stephan H, Stone JG, and Kettler D. 1988. Global and regional myocardial blood flow and metabolism during equipotent halothane and isoflurane anesthesia in patients with coronary artery disease. *Anesth Analg* 67:936-942.

Kim YD, Heim K, Wang YN, Lees D, and Myers AK. 1994. Effects of isoflurane on regional coronary blood flow and myocardial tissue pressure in chronically instrumented dogs. *Anesthesiology* 81:875-887.

Klocke FJ, Ellis AK, and Orlick AE. 1980. Sympathetic influences on coronary perfusion and evolving concepts of driving pressure, resistance, and transmural flow regulation. *Anesthesiology* 52:1-5.

Klocke FJ, Weinstein IR, Klocke JF, Romanowski RR, Anbar RD, Wallmeyer KW, Echt MP, Kraus DR, and Mates RE. 1981. Curvilinearity of the diastolic pressure-flow relationship in autoregulating and maximally vasodilated coronary beds; effects on estimates of zero-flow pressure and differences between zero-flow and intracavitary diastolic pressures. Role of capacitive effects in the determination of zero-flow pressure from long diastoles. *Basic Res Cardiol* 76:556-558.

Landoni G, Greco T, Biondi-Zoccai G, Nigro Neto C, Febres D, Pintaudi M, Pasin L, Cabrini L, Finco G, and Zangrillo A. 2013. Anaesthetic drugs and survival: a Bayesian network meta-analysis of randomized trials in cardiac surgery. *Br J Anaesth* 111:886-896. 10.1093/bja/aet231

Lang XE, Wang X, Zhang KR, Lv JY, Jin JH, and Li QS. 2013. Isoflurane preconditioning confers cardioprotection by activation of ALDH2. *PLoS One* 8:e52469. 10.1371/journal.pone.0052469

Leung JM, Goehner P, O'Kelly BF, Hollenberg M, Pineda N, Cason BA, and Mangano DT. 1991. Isoflurane anesthesia and myocardial ischemia: comparative risk versus sufentanil anesthesia in patients undergoing coronary artery bypass graft surgery. The SPI (Study of Perioperative Ischemia) Research Group. *Anesthesiology* 74:838-847.

Maas JJ, de Wilde RB, Aarts LP, Pinsky MR, and Jansen JR. 2012. Determination of vascular waterfall phenomenon by bedside measurement of mean systemic filling pressure and critical closing pressure in the intensive care unit. *Anesthesia and analgesia* 114:803.

Nanto S, Masuyama T, Takano Y, Hori M, and Nagata S. 2001. Determination of coronary zero flow pressure by analysis of the baseline pressure-flow relationship in humans. *Jpn Circ J* 65:793-796.

Priebe HJ, and Foex P. 1987. Isoflurane causes regional myocardial dysfunction in dogs with critical coronary artery stenoses. *Anesthesiology* 66:293-300.

Pulley DD, Kirvassilis GV, Keleromenos N, Kater K, Barzilai B, Genton RE, Efstathiou C, and Lappas DG. 1991. Regional and global myocardial circulatory and metabolic effects of isoflurane and halothane in patients with steal-prone coronary anatomy. *Anesthesiology* 75:756-766.

Shimada K, Sakanoue Y, Kobayashi Y, Ehara S, Hirose M, Nakamura Y, Fukuda D, Yamagishi H, Yoshiyama M, Takeuchi K, and Yoshikawa J. 2003. Assessment of myocardial viability using coronary zero flow pressure after successful angioplasty in patients with acute anterior myocardial infarction. *Heart* 89:71-76.

Takami Y, and Ina H. 2001. A simple method to determine anastomotic quality of coronary artery bypass grafting in the operating room. *Cardiovasc Surg* 9:499-503.

Walpoth BH, Bosshard A, Genyk I, Kipfer B, Berdat PA, Hess OM, Althaus U, and Carrel TP. 1998. Transit-time flow measurement for detection of early graft failure during myocardial revascularization. *Ann Thorac Surg* 66:1097-1100.

Yamamuro A, Akasaka T, Tamita K, Yamabe K, Katayama M, Takagi T, and Morioka S. 2002. Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. *Circulation* 106:3051-3056.
Table 1 (on next page)

Table 1
## Table 1

|                      | Control (n = 10) | Isoflurane (n = 10) | p-value |
|----------------------|-----------------|---------------------|---------|
| Age (years)          | 70 (58–79)      | 71 (51–81)          | 0.44    |
| Weight (kg)          | 80 (60–92)      | 75 (60–103)         | 0.68    |
| Height (cm)          | 168 (153–82)    | 168 (156–180)       | 0.68    |
| Gender (male/female) | 8/2             | 9/1                 | 0.53    |
| Body surface area (m²) | 1.89 (1.57–2.12) | 1.89 (1.59–2.09) | 0.97    |
| Coronary artery disease | 3 vessel disease, n = 7 | 3 vessel disease, n = 6 |
|                       | 2 vessel disease, n = 3 | 2 vessel disease, n = 3 |
|                       | 1 vessel disease, n = 1 | 1 vessel disease, n = 1 |
| Grafts (n)           | 4 (3–5)         | 4 (2–5)             |         |
| Aortic clamping time (minutes) | 78 (61–92) | 85 (45–112) | 0.68 |
| Reperfusion time (minutes) | 44 (32–65) | 40 (26–66) | 0.48 |
Table 2 (on next page)
|                  | Control | Isoflurane | Control | Isoflurane |
|------------------|---------|------------|---------|------------|
|                  | T15     | T30        | T15     | T30        |
| **CI (l min\(^{-1}\) m\(^{-2}\))** | 2.9 (2.3–3.6) | 2.7 (2.1–3.2) | 0.11     | 2.7 (1.6–5.7) | 2.6 (1.9–5.8) | 0.28 |
| **HR (min\(^{-1}\))**    | 89 (53–106) | 90 (56–106) | 0.65     | 99 (76–112) | 88 (74–100) | 0.15 |
| **MAP (mmHg)**         | 65 (47–80) | 66 (56–84) | 0.06     | 69 (59–85) | 57 (48–59) | 0.005 |
| **MDAP (mmHg)**        | 57 (45–64) | 60 (43–71) | 0.06     | 62 (53–79) | 50 (45–57) | 0.005 |
| **DDT (ms)**           | 447 (257–1215) | 489 (366–1070) | 0.60     | 721 (240–919) | 567 (339–937) | 0.33 |
| **CVP (mmHg)**         | 9 (7–16) | 9 (7–16) | **1.0**  | 10 (7–12) | 10 (7–13) | 0.82 |
| **CSP (mmHg)**         | 14 (8–18) | 13 (7–18) | 0.39     | 10 (5–20) | 10 (6–19) | 0.44 |
| **SVRI (dyn sec cm\(^{-5}\) m\(^{2}\))** | 1555 (809–2454) | 1716 (1355–2193) | 0.31     | 1730 (850–2969) | 1364 (699–1965) | 0.04 |
| **GEDI (ml m\(^{-2}\))** | 642 (541–895) | 652 (594–883) | 0.78     | 642 (457–834) | 617 (479–802) | 0.92 |
| **EVLWI (ml m\(^{-3}\))** | 6.8 (5.7–6.3) | 6.3 (5.0–6.3) | 0.62     | 7.4 (4.0–7.0) | 7.0 (4.3–7.0) | 0.16 |
|                         | 2)               | 10.0) | 8.7) | 10.7) | 10.0) |
|-------------------------|------------------|-------|------|-------|-------|
| **LVEDP (mmHg)**        |                  |       |      |       |       |
|                         | 16 (8–33)        | 15 (8–30) | 0.09 | 11 (8–37) | 13 (9–22) | 0.80 |
| **SVV (%)**             |                  |       |      |       |       |
|                         | 11 (6–17)        | 12 (5–18) | 0.64 | 12 (5–19) | 14 (8–16) | 0.43 |
| **dp/dt<sub>max</sub> (mmHg s<sup>-1</sup>)** | 766 (507–1063) | 763 (500–887) | 0.65 | 748 (510–1350) | 651 (340–1143) | 0.02 |
| **CFI (min<sup>-1</sup>)** | 4.2 (3.5–5.0) | 3.7 (2.8–5.0) | 0.05 | 4.6 (2.5–8.1) | 3.9 (3.1–7.4) | 0.16 |
| **COP (mmHg)**          | 39 (23–48)       | 42 (28–44) | 0.25 | 35 (26–59) | 34 (27–42) | 0.11 |
| **FLOW (ml/min)**       | 26 (10–38)       | 22 (9–53) | 0.72 | 29 (7–68) | 23 (11–50) | 0.24 |
| **Slope (B1)**          | 1.36 (0.48–2.71) | 1.29 (0.46–2.10) | 0.49 | 0.94 (0.50–4.82) | 2.03 (0.56–4.41) | 0.02 |
| **CVR from Slope 1/B1** | 0.74 (0.37–2.10) | 0.78 (0.48–2.17) | 0.49 | 1.06 (0.21–2.02) | 0.51 (0.23–1.79) | 0.007 |
| **CVR from CSP**        | 1.73 (1.21–3.92) | 1.83 (0.94–5.51) | 0.69 | 1.80 (0.78–8.83) | 1.35 (0.81–3.35) | 0.30 |
| **CVR from LVEDP**      | 1.66 (0.81–5.64) | 1.86 (0.61–5.64) | 0.49 | 1.68 (0.79–3.13) | 1.77 (0.73–3.13) | 0.06 |
| CVR from COP | 4.05) | 5.38) |
|--------------|--------|--------|
| 0.74 (0.37–2.07) | 0.78 (0.46–2.13) | 0.44 |
| 1.06 (0.21–2.02) | 0.51 (0.23–1.79) | 0.006 |
Table 3 (on next page)

Table 3
|                | Control vs Isoflurane | Control vs Isoflurane |
|----------------|-----------------------|-----------------------|
|                | T15 (p-value)         | T30 (p-value)         |
| CI (l min⁻¹ m⁻²) | 0.96                  | 0.90                  |
| HR (min⁻¹)      | 0.90                  | 0.85                  |
| MAP (mmHg)      | 0.06                  | 0.009                 |
| MDAP (mmHg)     | 0.06                  | 0.01                  |
| DDT (ms)        | 0.56                  | 0.90                  |
| CVP (mmHg)      | 0.96                  | 0.83                  |
| CSP (mmHg)      | 0.16                  | 0.11                  |
| SVRI (dyn sec cm⁻⁵ m²) | 0.51               | 0.05                  |
| GEDI (ml m⁻²)   | 0.69                  | 0.27                  |
| EVLWI (ml m⁻²)  | 0.31                  | 0.41                  |
| LVEDP (mmHg)    | 0.34                  | 0.47                  |
| SVV (%)         | 0.96                  | 0.57                  |
| dp/dtmax (mmHg s⁻¹) | 0.96               | 0.57                  |
| CFI (min⁻¹)     | 0.56                  | 0.76                  |
| COP (mmHg)      | 0.87                  | 0.11                  |
| FLOW (ml/min)   | 0.38                  | 0.79                  |
| Slope (B1)      | 0.79                  | 0.05                  |
| CVR from Slope 1/B1 | 0.87             | 0.14                  |
| CVR from CSP    | 0.83                  | 0.28                  |
| CVR from LVEDP  | 0.85                  | 0.39                  |
| CVR from COP | 0.73 | 0.10 |
**Table 4** (on next page)

Table 4
|                  | Control                  | Isoflurane               | T<sub>15</sub> vs T<sub>30</sub> |
|------------------|--------------------------|--------------------------|----------------------------------|
|                  | T<sub>15</sub>       | T<sub>30</sub>          | T<sub>15</sub>       | T<sub>30</sub>          |
| Hb<sub>art</sub> (g/dl) | 9.1 (7.5–10.0)          | 9.0 (7.8–10.9)          | 0.51                           | 9.2 (8.1–10.3)          | 9.2 (7.6–11.6)          | 0.91                      |
| S<sub>O</sub>2 (%) | 99 (94.1–99.6)          | 99 (93.7–99.9)          | 1.0                            | 99 (98.7–99.7)          | 99 (97.2–99.7)          | 0.31                      |
| P<sub>O</sub>2 (mmHg) | 163 (71–298)            | 153 (75–364)            | 0.43                           | 200 (124–293)            | 213 (141–277)            | 0.28                      |
| P<sub>CO</sub>2 (mmHg) | 46 (38–54)              | 48 (39.7–51.7)          | 0.08                           | 43 (35–55)              | 44 (34–50)              | 0.82                      |
| pH<sub>art</sub> | 7.35 (7.24–7.41)        | 7.35 (7.22–7.38)        | 0.08                           | 7.35 (7.24–7.44)        | 7.34 (7.28–7.45)        | 1.0                       |
| BE<sub>art</sub> (mmol/l) | -0.4 (-7.6–1.3)       | -1.2 (-7.2–1.1)         | 0.55                           | -1.4 (-4.4–1.2)         | -2.4 (-3.6–0.1)         | 0.31                      |
| SBIC<sub>art</sub> (mmol/l) | 24.1 (18.2–25.5) | 23.5 (18.5–25.5) | 0.58                           | 22.7 (20.7–24.2)         | 22.4 (21.4–24.6)         | 0.43                      |
| S<sub>O</sub>2 (%) | 49 (23.5–82.9)          | 46 (39.3–74.9)          | 0.49                           | 46 (29.7–74.5)          | 56 (33.1–80.3)          | 0.05                      |
| P<sub>O</sub>2 (mmHg) | 26 (19–51)              | 27 (24–43)              | 0.70                           | 27 (19–44)              | 33 (22–49)              | 0.006                     |
| P<sub>CO</sub>2 (mmHg) | 56 (38–64)              | 58 (48–62)              | 0.06                           | 54 (38–66)              | 55 (40–64)              | 1.0                       |
| pH<sub>art</sub> | 7.30 (7.14–7.35)        | 7.30 (7.17–7.32)        | 0.13                           | 7.30 (7.19–7.42)        | 7.28 (7.23–7.40)        | 0.30                      |
| BE<sub>art</sub> (mmol/l) | 0.3 (-7.9–2.0)       | -0.1 (-6.8–1.9)         | 0.91                           | -1.4 (-3.9–0.7)         | -2.2 (-3.4–0.2)         | 0.02                      |
| SBIC<sub>art</sub> (mmol/l) | 23.9 (17.0–25.3) | 23.7 (18.1–25.2) | 0.84                           | 22.6 (20.8–24.3)         | 21.9 (21.3–24.2)         | 0.03                      |
| Lactate<sub>art</sub> (mmol/l) | 1.0 (0.6–5.8)       | 1.0 (0.5–5.3)           | 0.16                           | 1.8 (1.0–3.0)           | 2.0 (0.8–2.7)           | 0.39                      |
| Isoflurane<sub>art</sub> (µg/dl) | 0                      | 0                        | 0                               | 0                      | 1.4 (0.8–2.3)           |                           |
**Table 5** (on next page)

Table5
|                | Control vs Isoflurane | Control vs Isoflurane |
|----------------|-----------------------|-----------------------|
|                | $T_{15}$ (p-value)    | $T_{30}$ (p-value)    |
| Hb$_{art}$ (g/dl) | 0.43                  | 0.57                  |
| $S_aO_2$ (%)     | 0.17                  | 0.32                  |
| $P_aO_2$ (mmHg)  | 0.32                  | 0.08                  |
| $P_aCO_2$ (mmHg) | 0.39                  | 0.12                  |
| pH$_{art}$       | 0.35                  | 0.68                  |
| BE$_{art}$ (mmol/l) | 0.22                | 0.25                  |
| SBIC$_{art}$ (mmol/l) | 0.19                | 0.25                  |
| $S_{cs}O_2$ (%)  | 0.85                  | 0.17                  |
| $P_{cs}O_2$ (mmHg) | 0.58                 | 0.17                  |
| $P_{cs}CO_2$ (mmHg) | 0.80               | 0.35                  |
| pH$_{cs}$        | 0.79                  | 0.85                  |
| BE$_{cs}$ (mmol/l) | 0.53                 | 0.17                  |
| SBIC$_{cs}$ (mmol/l) | 0.63                | 0.16                  |
| Lactate$_{cs}$ (mmol/l) | 0.06                 | 0.03                  |
| Isoflurane$_{cs}$ (µg/dl) |                |                       |